Should we avoid using ketoconazole in patients with severe Cushing’s syndrome and increased levels of liver enzymes?

in European Journal of Endocrinology
Correspondence should be addressed to A Tabarin; Email: antoine.tabarin@chu-bordeaux.fr
Restricted access

 

     European Society of Endocrinology

Related Articles

Article Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 517 517 13
Full Text Views 550 550 4
PDF Downloads 119 119 0

Altmetrics

Figures

  • View in gallery

    Evolution of mean levels of liver enzymes and UFC during the first month of ketoconazole administration in nine patients with severe Cushing’s syndrome. ALT, alanine aminotransferase; AST, aspartate aminotransferase; UFC, urinary free cortisol; ULN, upper limit of normal.

References

  • 1

    YoungJBertheratJVantyghemMCChabreOSenoussiSChadarevianRCastinettiF & Compassionalte use Programme. Hepatic safety of ketoconazole in Cushing’s syndrome: results of a Compassionate Use Programme in France. European Journal of Endocrinology 2018 178 447458. (https://doi.org/10.1530/EJE-17-0886)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    NiemanLKBillerBMKFindlingJWMuradMHNewell-PriceJSavageMOTabarinA & Endocrine Society. Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2015 100 28072831. (https://doi.org/10.1210/jc.2015-1818)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3

    CorcuffJ-BYoungJMasquefa-GiraudPChansonPBaudinETabarinA. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology 2015 172 473481. (https://doi.org/10.1530/EJE-14-0913)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    KamenickýPDroumaguetCSalenaveSBlanchardAJublancCGautierJ-FBrailly-TabardSLeboulleuxSSchlumbergerMBaudinE Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 27962804. (https://doi.org/10.1210/jc.2011-0536)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    HazlehurstJMTomlinsonJW. Mechanisms in endocrinology: non-alcoholic fatty liver disease in common endocrine disorders. European Journal of Endocrinology 2013 169 R27R37. (https://doi.org/10.1530/EJE-13-0296)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    CastinettiFGuignatLGiraudPMullerMKamenickyPDruiDCaronPLucaFDonadilleBVantyghemMC Ketoconazole in Cushing’s disease: is it worth a try? Journal of Clinical Endocrinology and Metabolism 2014 99 16231630. (https://doi.org/10.1210/jc.2013-3628)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    VerhelstJATrainerPJHowlettTAPerryLReesLHGrossmanABWassJAHSesserGM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clinical Endocrinology 1991 35 169178. (https://doi.org/10.1111/j.1365-2265.1991.tb03517.x)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8

    PivonelloRDe LeoMCozzolinoAColaoA. The treatment of Cushing’s disease. Endocrine Reviews 2015 36 385486. (https://doi.org/10.1210/er.2013-1048)

Cited By

PubMed

Google Scholar